P atients with acute ischemic stroke (AIS) because of large vessel occlusion (LVO) benefit 1 from mechanical thrombectomy (MT). [2] [3] [4] [5] [6] Robust pial collaterals have been correlated with a greater likelihood of achieving a good outcome after treatment when patients present within 6 hours of symptom onset, 7 and collaterals are commonly assessed by computed tomography angiography (CTA). However, CTA-based measures of collaterals do not provide brain perfusion information, and typical CTA scores cannot be applied to magnetic resonance imaging protocols with time of flight angiography.
A more quantitative measure of collaterals could be beneficial to determine patient eligibility for MT at a comprehensive stroke center or even at a primary center looking to transfer patients for endovascular treatment. In addition, a measure of collateral circulation that provides information about perfusion of the brain tissue would be expected to provide more meaningful information about how well pial collaterals provide adequate blood flow to the brain.
The hypoperfusion intensity ratio (HIR) is derived from perfusion imaging and represents the volumetric ratio of tissue with a time-to-maximum (TMax) >10 seconds and TMax >6 seconds. 8 Well perfused tissue is more likely to have a higher percentage of less prolonged blood flow, and a low HIR reflects favorable collateral status.
We hypothesized that AIS patients with LVO who underwent MT (MT+) would be more likely to exhibit favorable collaterals on HIR compared with those who did not undergo MT (MT−). We also hypothesized that AIS patients with a LVO and a target mismatch who did not undergo MT because of mild symptoms (National Institutes of Health Stroke Scale [NIHSS] <6 1 ) were more likely to have a favorable HIR Background and Purpose-Hypoperfusion intensity ratio (HIR) is associated with collateral status in acute ischemic stroke patients with anterior circulation large vessel occlusion. We assessed whether HIR was correlated to patient eligibility for mechanical thrombectomy (MT). Methods-We performed a retrospective cohort study of consecutive acute ischemic stroke patients with a proximal middle cerebral artery or internal carotid artery occlusion who underwent MT triage with computed tomography or magnetic resonance perfusion imaging. Clinical data, ischemic core (mL), HIR (defined as time-to-maximum [TMax] >10 seconds/ TMax >6 seconds), mismatch volume between core and penumbra, and MT details were assessed. Primary outcome was favorable HIR collateral score (HIR <0.4) between patients who underwent MT (MT+) and those who did not (MT−) according to American Heart Association guidelines both in the <6 hours and 6 to 24 hours windows. Secondary outcomes were favorable HIR score in MT− subgroups (National Institutes of Health Stroke Scale <6 versus core >70 mL) and core-penumbra mismatch volumes. Patients who did not meet guidelines were not included. 
Results-We

Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
The study protocol was approved by the institutional review board and complied with the Health Insurance Portability and Accountability Act. Patient informed consent was waived by our review board.
Population and Clinical Data
We performed a retrospective cohort study of consecutive patients with AIS because of anterior circulation LVO evaluated for MT at our comprehensive stroke center between May 2013 and March 2018.
Study inclusion criteria were ( Figure 1 ) prestroke modified Rankin Scale score of 0-1, AIS due to LVO (internal carotid artery and first segment of the middle cerebral artery segment 1 [M1]), age ≥18 years, treatment initiated (groin puncture) within 6 hours 1 of symptom onset, and MT treatment triage by CT or magnetic resonance imaging that included perfusion imaging. Patients who met inclusion criteria for the DEFUSE 3 trial (Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution) were also included in this analysis. 5 Clinical data, such as sex, age, initial NIHSS, imaging triage modality, intravenous-thrombolysis administration, LVO location, and side, were determined from our prospectively maintained electronic database.
Imaging Analysis
Ischemic core (mL), HIR, and core/perfusion mismatch 9 imaging data were determined using an automated software program (RAPID, iSchemaView, Menlo Park). Ischemic core was the volume of restricted diffusion on magnetic resonance imaging diffusion weighted imaging or the volume of tissues with a 70% in cerebral blood flow relative to the unaffected contralateral cerebral hemisphere.
Core-perfusion mismatch was defined as the difference between the TMax >6 seconds lesion volume and the ischemic core volume. Mismatch ratio was calculated as the ratio between the TMax >6 seconds lesion volume and the core volume.
HIR was defined as the volume of tissue with TMax >10 seconds divided by the volume of tissue with TMax >6 seconds on CT or MR perfusion studies.
8 Favorable (good) collaterals were defined as HIR <0.4, and poor collaterals were defined as HIR ≥0.4 based on previously published thresholds. 8 
Outcomes and Statistical Analyses
Primary outcome was favorable HIR collateral score (HIR <0.4, Figure 2 ). Secondary outcomes were baseline mismatch volume and mismatch ratio, NIHSS shift (difference between baseline and discharge NIHSS score).
Nominal variables were first summarized using frequency descriptive analysis then compared using the Fisher exact test. Continuous variables were summarized using mean, SD, median, quartiles, and interquartile range, then tested using Welch t test (2 tailed t test assuming unequal variances). Normality of the variables was tested by the Shapiro-Wilk test. When there were >2 groups, the Freeman-Halton extension of Fisher exact test was used. A univariate analysis was performed. Pearson correlation was calculated to test correlation between HIR or mismatch ratio and MT treatment decision. Statistical significance was set at the P=0.05 level. All statistical analyses were performed with XLSTAT (Addinsoft, New York City, NY).
Results
From May 2013 to March 2018, a total of 352 patients were transferred for MT, and 197 met inclusion criteria. There were 145 patients in the MT+ group and 52 patients in the MT− group. Among MT− patients, 43 (83%) did not undergo treatment because of a large core infarction at baseline or a matched core-penumbra profile, and 9 (17%) did not undergo treatment because of mild symptoms (NIHSS <6 1 ; Figure 1 significance (P=0.06). No other significant differences in patient characteristics were identified. These results are summarized in Table 1 .
MT+ patients had a higher frequency of left-sided strokes (55% versus 37%; P=0.02; Table 2 ). Median ischemic core volume was significantly lower in MT+ group (12 mL) compared with MT− (117.5 mL; P<0.001). Median mismatch volume between the core and penumbra was higher in MT+ patients (96 versus 27 mL in MT−, P<0.001), and median mismatch ratio was lower in MT+ patients (1. Table 2 ). When MT+ patients were dichotomized into favorable (HIR <0.4) and unfavorable (≥0.4) subgroups, patients with favorable HIR (<0.4) had significantly smaller core volumes, smaller TMax >6 seconds and TMax >10 seconds volumes and smaller mismatch volumes (Table in the Table 3 ). Clinical outcomes between MT+ patients with HIR <0.4 and ≥0.4 were not significantly different in terms of NIHSS at day 1 and early NIHSS shift, which is consistent with a treatment benefit by thrombectomy in both of these groups.
We performed a subgroup analysis of MT− patients, who were separated into patients with NIHSS <6 (9/52, 17%) versus NIHSS ≥6. MT− patients with NIHSS <6 all had a mismatch between their core and penumbra volumes, but they were not treated because of mild symptoms. By contrast, patients with NIHSS ≥6 in the MT− group (43/52, 83%) all had large baseline core infarctions (>70 mL). In these MT− patients, HIR was significantly lower in patients with NIHSS<6 (median HIR 0. Table 4 ).
Given the inherent relationship between the mismatch profile on perfusion imaging and the HIR that is also measured by perfusion imaging, we performed a Pearson correlation analysis to determine the influence of these 2 variables on MT eligibility. HIR (−0.447 [−0.552 to −0.328], P<0.0001) was more strongly correlated with the decision 
Discussion
In this study, we found a favorable HIR (<0.4) to be strongly correlated with the decision to perform MT. These results indicate that patients eligible for MT have superior collaterals and superior tissue perfusion compared with patients who are not eligible for MT. Our study is the first, to our knowledge, to evaluate HIR as a factor for determining MT eligibility. HIR is derived from perfusion imaging, and a low HIR reflects favorable collateral status. 8, 10, 11 Prior studies have correlated HIR with collateral circulation, cerebral infarct growth, and clinical outcome after MT, 8, 12 which is consistent with our findings. In our study, a low HIR was associated with smaller core infarctions at baseline as well as smaller mismatch volumes. HIR has been associated with both collateral blood flow in AIS with an anterior circulation occlusion 8 and stroke severity at baseline 13 in patients treated by MT. Furthermore, HIR is measured through automated perfusion imaging software, and it may be measured at a referring hospital to facilitate patient transfer to a comprehensive stroke center that offers MT. 14 HIR has been demonstrated to be a robust and reliable measure of microvascular collateral flow in stroke. 8, 10, 11, 13, 15 Similarly, our findings are consistent with superior tissue microvascular perfusion in patients with a favorable HIR given their small core infarctions at the time of imaging evaluation. Collateral measurement by HIR is different from collateral assessment on maximum-intensity projection images from CTA, which is more commonly used. HIR provides a more nuanced measure of tissue level collateral blood flow, which may be more meaningful in the context of acute stroke because of an LVO.
The automated processing of these data may allow for more generalized evaluation of these patients by treating neurologists and neurointerventionalists, even when the patient is being evaluated at an outside facility. Our findings also suggest that HIR may then be a useful variable for MT triage of symptomatic patients before transfer to a referring hospital to a hospital that offers thrombectomy, although this question requires additional study.
Interestingly, AIS patients with LVO and a target mismatch on perfusion imaging who were not treated because of mild symptoms (NIHSS <6) had a favorable HIR (<0.4) compared with MT− who were not treated because of a large core infarction on baseline imaging. These findings are consistent with excellent collateral perfusion in patients with mild symptoms. It will be of interest to determine if HIR is a useful prognostic marker of outcome and collateral durability in these patients, in whom there is ongoing debate as to the benefit of MT.
It is possible that HIR was higher in MT− patients because they had larger core infarctions. However, poor collaterals depicted by high HIR at baseline before MT has been associated with a faster infarct growth. 8 We might then extrapolate and hypothesize that an earlier imaging of these patients would have shown the same results as HIR has been shown to often be stable between 2 perfusion evaluations. 11 Indeed, one of the confounding factors might have been a different median onset to imaging delay between MT + and − groups, although this trend was not statistically significant (P=0.06) despite being potentially consequential in MT− patients. Our results have implications for future stroke studies. The impact of core volume and collateral robustness assessed by HIR should be addressed in future randomized trials to understand better the influence of these variables on patient MT eligibility and outcome after treatment. Additional studies should also investigate whether HIR has utility as a prognostic factor in the context of MT. Last, future studies should address the use of HIR as an independent factor in MT treatment eligibility. For example, determination of HIR before patient transfer from a referring hospital may provide an objective measure of MT eligibility.
Limitations
There are several limitations to our study. The retrospective design and the lack of randomization based on HIR profile may bias our results. The single-center design and use of magnetic resonance imaging for baseline imaging with automated postprocessing in this cohort may also limit the generalizability of our results. The exclusion of patients who did not undergo perfusion imaging and imaging selection for MT that included patients with a core infarction <70 mL and a target mismatch may also introduce bias. However, our inclusion criteria met AHA guidelines, serving as gold-standard.
Conclusions
Patients who meet American Heart Association guidelines for thrombectomy are more likely to have a favorable HIR, which is most consistent with good collaterals. Favorable HIR is strongly associated with the decision to perform MT and may be a useful marker of MT eligibility. Further prospective studies should determine if collaterals assessment 
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by HIR at primary stroke centers before transfer to a comprehensive stroke center is a meaningful measure of MT treatment eligibility.
